《新股消息》和譽-B(02256.HK)今日起招股 入場費25,171.12元
臨牀階段的生物製藥公司和譽-B(02256.HK)公佈全球公開發售1.41億股,其中10%於本港作公開發售,招股價介乎12.16元至12.46元,每手2,000股,入場費25,171.12元。今日起招股,至下週三(10月6日)截止,預期同日定價,10月13日掛牌。聯席保薦人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人爲摩根士丹利及摩根大通。聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人爲中金公司。聯席賬簿管理人及聯席牽頭經辦人爲興證國際、海通國際、匯豐及華泰國際。
和譽已戰略性地設計及開發由14個專注於腫瘤學的候選藥物組成的管線,包括五種處於臨牀階段的候選藥物。
公司與數名基石投資者簽訂協議,認購總金額1.28億美元等值股份,其中AIHC認購600萬美元,Janchor Partners Pan-Asian Master Fund認購700萬美元,Lake Bleu Prime、OrbiMed基金、Aranda、Hudson Bay、Vivo基金及BlackRock Global Funds-World Healthscience Fund各認購1,000萬美元,Epsomite認購1,500萬美元,LAV及UBS基金各認購2,000萬美元。
假設最終發售價爲招股價區間中間價12.31元,公司料是次上市將集資15.85億元,其中19.7%用於進行中的及未來的研發,包括核心候選產品ABSK011已計劃的臨牀試驗、註冊文件的編制及未來商業化;32.6%用於進行中的及未來的研發,包括核心候選產品ABSK091(AZD4547)已計劃的臨牀試驗、註冊文件的編制及未來商業化;28%用於其他臨牀階段產品及管線的候選產品;8.4%用於臨牀前研究;6.3%用於建造上海生產設施;其餘5%用作營運資金及一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.